Leukaemic relapse of anaplastic large cell lymphoma, ALK negative. 2021

Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
Hematology Oncology, Augusta University, Augusta, Georgia, USA nbnrj@hotmail.com.

Anaplastic large cell lymphoma (ALCL), ALK negative (ALK-) is an aggressive lymphoproliferative disorder of mature T lymphocytes characterised by hallmark cells, CD30 positivity and lacking ALK protein expression. ALCL, ALK- has to be differentiated from peripheral T-cell lymphoma-not otherwise specified and classical Hodgkin's lymphoma. ALK- anaplastic large cell leukaemia should be considered in a patient with a history of ALCL, ALK- presenting with new leukaemia. We report a rare presentation of relapsed ALCL, ALK- with leukaemia after autologous stem cell transplantation in a 57-year-old male. Leukaemia, either as primary presentation or secondary transformation confers worse prognosis in ALCL, ALK- with very few cases reported so far. Emergency resuscitation with leukapheresis and treatment of tumour lysis syndrome along with supportive care should be followed by combination chemotherapy. Brentuximab vedotin and stem cell transplantation are the backbone of treatment for relapsed/refractory disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077548 Anaplastic Lymphoma Kinase A receptor tyrosine kinase that is essential for development and differentiation of the nervous system in response to secreted growth factors. It phosphorylates the first tyrosine of the Y-x-x-x-Y-Y motif of targets that include PROTO-ONCOGENE PROTEINS C-CBL; INSULIN RECEPTOR SUBSTRATE-1; and MITOGEN-ACTIVATED PROTEIN KINASES, leading to activation of the MAPK signaling pathway and cell proliferation. A chromosomal aberration involving the ALK gene results in its constitutive expression in some cases of NON-HODGKIN LYMPHOMA. ALK Kinase,ALK Tyrosine Kinase Receptor,Anaplastic Lymphoma Receptor Tyrosine Kinase,CD246 Antigen,NPM-ALK,Nucleophosmin-Anaplastic Lymphoma Kinase,Nucleophosmin Anaplastic Lymphoma Kinase
D014182 Transplantation, Autologous Transplantation of an individual's own tissue from one site to another site. Autografting,Autologous Transplantation,Autotransplantation,Autograftings,Autologous Transplantations,Autotransplantations,Transplantations, Autologous
D017728 Lymphoma, Large-Cell, Anaplastic A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS. Anaplastic Large-Cell Lymphoma,CD30-Positive Anaplastic Large-Cell Lymphoma,Lymphoma, Large-Cell, Ki-1,CD30+ Anaplastic Large-Cell Lymphoma,Ki-1 Lymphoma,Systemic Anaplastic Large-Cell Lymphoma,Anaplastic Large Cell Lymphoma,Anaplastic Large-Cell Lymphomas,CD30 Positive Anaplastic Large Cell Lymphoma,CD30+ Anaplastic Large Cell Lymphoma,Ki 1 Lymphoma,Ki-1 Lymphomas,Large-Cell Lymphoma, Anaplastic,Large-Cell Lymphomas, Anaplastic,Lymphoma, Anaplastic Large-Cell,Lymphoma, Ki-1,Lymphomas, Anaplastic Large-Cell,Lymphomas, Ki-1,Systemic Anaplastic Large Cell Lymphoma
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell
D020794 Receptor Protein-Tyrosine Kinases A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity. PTK Receptor,Receptors, Protein-Tyrosine Kinase,Tyrosine Kinase Linked Receptor,Tyrosine Kinase Linked Receptors,Tyrosine Kinase Receptor,Tyrosine Kinase Receptors,PTK Receptors,Protein-Tyrosine Kinase Receptor,Receptor Protein-Tyrosine Kinase,Kinase Receptor, Tyrosine,Kinase, Receptor Protein-Tyrosine,Kinases, Receptor Protein-Tyrosine,Protein-Tyrosine Kinase Receptors,Protein-Tyrosine Kinase, Receptor,Protein-Tyrosine Kinases, Receptor,Receptor Protein Tyrosine Kinase,Receptor Protein Tyrosine Kinases,Receptor, PTK,Receptor, Protein-Tyrosine Kinase,Receptor, Tyrosine Kinase,Receptors, PTK,Receptors, Protein Tyrosine Kinase

Related Publications

Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
January 2016, Blood,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
February 2013, Critical reviews in oncology/hematology,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
June 2011, Pediatric reports,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
January 2020, Academic pathology,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
January 2015, Pathology,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
May 2007, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
January 2021, British journal of haematology,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
February 2023, Blood,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
April 2011, Zhongguo shi yan xue ye xue za zhi,
Nabin Raj Karki, and Kristine Badin, and Natasha Savage, and Locke Bryan
November 2017, American journal of hematology,
Copied contents to your clipboard!